生物技术公司Mosanna Therapeutics获得8000万美元A轮融资，用于推进睡眠呼吸暂停鼻喷剂的研究-动脉网

EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

CISION 等信源发布 2025-06-09 22:51



可切换为仅中文







Series A Funding will be used to advance Mosanna's nasal spray therapy through Phase 2 Clinical Trials

A轮融资将用于推动Mosanna的鼻喷雾疗法通过二期临床试验。

Biotech veteran

生物技术资深人士

David Weber

大卫·韦伯

has been appointed CEO to lead the company through clinical development

已被任命为首席执行官，以领导公司进行临床开发

Obstructive sleep apnea (OSA) affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options

阻塞性睡眠呼吸暂停 (OSA) 影响着全球近 10 亿人，其中大多数人未被诊断出来，且现有的治疗方案未能充分满足需求。

STOCKHOLM

斯德哥尔摩

，

June 9, 2025

2025年6月9日

/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics ('the Company'). The clinical-stage biotech company headquartered in

/PRNewswire/ -- EQT生命科学公司很高兴地宣布，LSP 7基金已投资于Mosanna Therapeutics（“该公司”）。这家临床阶段的生物技术公司总部位于

Basel, Switzerland

瑞士巴塞尔

, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body's natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF)..

，正在开发一种易于使用的夜间鼻喷剂，用于治疗阻塞性睡眠呼吸暂停（OSA），旨在恢复身体的自然气道控制。本轮融资由EQT生命科学和Pivotal bioVenture Partners领投，Forbion、Broadview Ventures和Norwest作为共同牵头投资者参与。回归投资者包括创始投资者Forty51 Ventures以及Supermoon Capital和高技术创业基金（HTGF）。

'What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue' said

“Mosanna 的独特之处在于它对睡眠呼吸暂停采取了完全不同的方法，将其视为一种神经和肌肉功能障碍，而不是纯粹的机械问题，”

Daniela Begolo

丹妮拉·贝戈洛

, Ph.D., Managing Director at EQT Life Sciences, who will be joining the Board of Directors. 'MOS118 is the first therapy with the potential to restore the body's natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.' .

博士，EQT生命科学公司的董事总经理，将加入董事会。'MOS118是第一个有可能通过鼻喷剂的简便方式恢复人体自然气道反射的疗法。MOS118有潜力显著提高长期被忽视的患者群体的依从性和治疗效果。'

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents.

OSA是最常见的睡眠相关呼吸障碍，影响全球约10亿人。如果不加以治疗，OSA与多种严重的健康风险相关，包括高血压、心血管疾病、中风、抑郁和白天过度嗜睡，并可能导致工作场所和交通事故。

Despite OSA's prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. .

尽管阻塞性睡眠呼吸暂停症 (OSA) 非常普遍，但其治疗方法主要集中在通常令人不适且具有干扰性的机械解决方案上。

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body's natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that in OSA patients, the natural airway reflex becomes less active at night, leading to a loss of airway patency and the occurrence of apnea.

Mosanna正在为睡眠呼吸暂停患者开创一种药物解决方案，即夜间使用的鼻喷剂MOS118，它有助于恢复身体的自然气道反射。MOS118针对负责维持气道通畅的上气道肌肉。研究表明，在阻塞性睡眠呼吸暂停（OSA）患者中，夜间自然气道反射的活跃性降低，导致气道通畅性丧失并引发呼吸暂停。

The new funding will support the advancement of MOS118 through Phase 2 development while also supporting the expansion of Mosanna's pipeline. .

新资金将支持MOS118的第二阶段开发，同时支持Mosanna产品线的扩展。

Mosanna also appointed veteran biotech leader

莫斯安娜还任命了资深生物技术领导者

David Weber

大卫·韦伯

, Ph.D., as President and Chief Executive Officer to guide Mosanna's next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna's Board of Directors. .

，博士，担任总裁兼首席执行官，以引领Mosanna的下一阶段增长。韦伯博士拥有超过30年的药物开发、资本形成和企业战略经验，曾带领多家上市和私营生命科学公司的团队。韦伯博士还被任命为Mosanna董事会成员。

'Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,' said Dr. Weber. 'No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds.

“Mosanna正在采取一种真正变革性的睡眠呼吸暂停治疗方法——提供一种非侵入性、非机械的解决方案，旨在无缝融入日常生活，”韦伯博士说。“没有人会在清醒时出现睡眠呼吸暂停，因为我们的身体会本能地保持气道畅通。Mosanna只是帮助在睡眠期间恢复这种自然反射——提供了一种鼻喷剂替代那些侵入性的机械手段。”

With this funding, we're accelerating development to bring this groundbreaking treatment to patients who desperately need better options.' .

通过这项资金，我们正在加速开发，以将这种突破性的治疗带给迫切需要更好选择的患者。

Contact

联系人

EQT Press Office,

EQT新闻办公室，

press@eqtpartners.com

This information was brought to you by Cision

此信息由Cision提供给您

http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-leads-usd-80-million-series-a-funding-round-in-mosanna-therapeutics-to-advance-sle,c4160762

The following files are available for download: